英文名稱(chēng) | Linifanib(ABT-869; AL-39324; RG3635) |
---|---|
中文名稱(chēng) | 1-(4-(3-氨基-1H-吲唑-4-基)苯基)-3-(2-氟-5-甲基苯基)脲; 利尼伐尼 |
CAS號(hào) | 796967-16-3 |
分子式 | C21H18FN5O |
分子量 | 375.40 |
MDL | MFCD11840918 |
外觀(guān) | White to gray powder |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
---|---|---|---|---|
5 mg | 3-5days | ¥400.00 | 登錄后可見(jiàn) | |
10 mg | 3-5days | ¥650.00 | 登錄后可見(jiàn) | |
25 mg | 3-5days | ¥1160.00 | 登錄后可見(jiàn) |
英文名稱(chēng) | Linifanib(ABT-869; AL-39324; RG3635) |
---|---|
中文名稱(chēng) | 1-(4-(3-氨基-1H-吲唑-4-基)苯基)-3-(2-氟-5-甲基苯基)脲; 利尼伐尼 |
CAS號(hào) | 796967-16-3 |
分子式 | C21H18FN5O |
分子量 | 375.40 |
MDL | MFCD11840918 |
外觀(guān) | White to gray powder |
Linifanib (formerly RG3635, ABT869, AL39324) is an orally bioavailable and ATP-competitive inhibitor of multiple kinases (e.g. VEGFR/PDGFR) with potential antitumor activity. Its IC50 values are 4 nM, 3 nM, 3 nM/4 nM, and 66 nM for KDR, CSF-1R, Flt-1/3, and PDGFRβ, respectively. Linifanib has strong antitumor efficaciousness in vivo and outstanding anti-proliferative activity in vitro.